Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 1
2008 5
2009 8
2010 5
2011 6
2012 10
2013 9
2014 6
2015 7
2016 11
2017 12
2018 20
2019 23
2020 20
2021 20
2022 20
2023 20
2024 32
2025 19

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

244 results

Results by year

Filters applied: . Clear all
Page 1
Smouldering multiple sclerosis: the 'real MS'.
Giovannoni G, Popescu V, Wuerfel J, Hellwig K, Iacobaeus E, Jensen MB, García-Domínguez JM, Sousa L, De Rossi N, Hupperts R, Fenu G, Bodini B, Kuusisto HM, Stankoff B, Lycke J, Airas L, Granziera C, Scalfari A. Giovannoni G, et al. Ther Adv Neurol Disord. 2022 Jan 25;15:17562864211066751. doi: 10.1177/17562864211066751. eCollection 2022. Ther Adv Neurol Disord. 2022. PMID: 35096143 Free PMC article. Review.
We hypothesise that therapeutically targeting a state of 'no evident inflammatory disease activity' (NEIDA) cannot sufficiently prevent disability accumulation in MS, meaning that treatment should also focus on other brain and spinal cord pathological processes contributin …
We hypothesise that therapeutically targeting a state of 'no evident inflammatory disease activity' (NEIDA) cannot sufficiently prevent disa …
Imaging in neuro-oncology.
Nandu H, Wen PY, Huang RY. Nandu H, et al. Ther Adv Neurol Disord. 2018 Feb 28;11:1756286418759865. doi: 10.1177/1756286418759865. eCollection 2018. Ther Adv Neurol Disord. 2018. PMID: 29511385 Free PMC article. Review.
Imaging plays several key roles in managing brain tumors, including diagnosis, prognosis, and treatment response assessment. Ongoing challenges remain as new therapies emerge and there are urgent needs to find accurate and clinically feasible methods to noninvasively evalu …
Imaging plays several key roles in managing brain tumors, including diagnosis, prognosis, and treatment response assessment. Ongoing …
Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper).
Wiendl H, Gold R, Berger T, Derfuss T, Linker R, Mäurer M, Aktas O, Baum K, Berghoff M, Bittner S, Chan A, Czaplinski A, Deisenhammer F, Di Pauli F, Du Pasquier R, Enzinger C, Fertl E, Gass A, Gehring K, Gobbi C, Goebels N, Guger M, Haghikia A, Hartung HP, Heidenreich F, Hoffmann O, Kallmann B, Kleinschnitz C, Klotz L, Leussink VI, Leutmezer F, Limmroth V, Lünemann JD, Lutterotti A, Meuth SG, Meyding-Lamadé U, Platten M, Rieckmann P, Schmidt S, Tumani H, Weber F, Weber MS, Zettl UK, Ziemssen T, Zipp F; ‘Multiple Sclerosis Therapy Consensus Group’ (MSTCG). Wiendl H, et al. Ther Adv Neurol Disord. 2021 Aug 18;14:17562864211039648. doi: 10.1177/17562864211039648. eCollection 2021. Ther Adv Neurol Disord. 2021. PMID: 34422112 Free PMC article. Review.
A review of Bruton's tyrosine kinase inhibitors in multiple sclerosis.
Airas L, Bermel RA, Chitnis T, Hartung HP, Nakahara J, Stuve O, Williams MJ, Kieseier BC, Wiendl H. Airas L, et al. Ther Adv Neurol Disord. 2024 Apr 17;17:17562864241233041. doi: 10.1177/17562864241233041. eCollection 2024. Ther Adv Neurol Disord. 2024. PMID: 38638671 Free PMC article. Review.
New developments in brain metastases.
Berghoff AS, Preusser M. Berghoff AS, et al. Ther Adv Neurol Disord. 2018 Jun 28;11:1756286418785502. doi: 10.1177/1756286418785502. eCollection 2018. Ther Adv Neurol Disord. 2018. PMID: 30034538 Free PMC article. Review.
Patients with brain metastases (BM) are a population of high clinical need for new therapeutic approaches due to, as yet, very impaired survival prognosis. ...New developments in the treatment of BM patients aim to reduce the side effects of local therapies, for example, b …
Patients with brain metastases (BM) are a population of high clinical need for new therapeutic approaches due to, as yet, very impair …
The potential of lasmiditan in migraine.
Mecklenburg J, Raffaelli B, Neeb L, Sanchez Del Rio M, Reuter U. Mecklenburg J, et al. Ther Adv Neurol Disord. 2020 Oct 21;13:1756286420967847. doi: 10.1177/1756286420967847. eCollection 2020. Ther Adv Neurol Disord. 2020. PMID: 33403005 Free PMC article. Review.
Treatment-related side effects seem to be related to the rapid penetration of the drug into the brain and include dizziness, paresthesia and drowsiness, mostly of mild to moderate intensity. ...
Treatment-related side effects seem to be related to the rapid penetration of the drug into the brain and include dizziness, paresthe …
Association of biological sex with clinical outcomes and biomarkers of Alzheimer's disease in adults with Down syndrome.
Iulita MF, Bejanin A, Vilaplana E, Carmona-Iragui M, Benejam B, Videla L, Barroeta I, Fernández S, Altuna M, Pegueroles J, Montal V, Valldeneu S, Giménez S, González-Ortiz S, Torres S, El Bounasri El Bennadi S, Padilla C, Rozalem Aranha M, Estellés T, Illán-Gala I, Belbin O, Valle-Tamayo N, Camacho V, Blessing E, Osorio RS, Videla S, Lehmann S, Holland AJ, Zetterberg H, Blennow K, Alcolea D, Clarimón J, Zaman SH, Blesa R, Lleó A, Fortea J. Iulita MF, et al. Brain Commun. 2023 Mar 17;5(2):fcad074. doi: 10.1093/braincomms/fcad074. eCollection 2023. Brain Commun. 2023. PMID: 37056479 Free PMC article.
They underwent assessment with the Cambridge Cognitive Examination for Older Adults with Down Syndrome, modified cued recall test and determinations of brain amyloidosis (CSF amyloid-beta 42 / 40 and amyloid-PET), tau pathology (CSF and plasma phosphorylated-tau181) and ne …
They underwent assessment with the Cambridge Cognitive Examination for Older Adults with Down Syndrome, modified cued recall test and determ …
Advances in brain imaging in multiple sclerosis.
Cortese R, Collorone S, Ciccarelli O, Toosy AT. Cortese R, et al. Ther Adv Neurol Disord. 2019 Jun 27;12:1756286419859722. doi: 10.1177/1756286419859722. eCollection 2019. Ther Adv Neurol Disord. 2019. PMID: 31275430 Free PMC article. Review.
Brain imaging is increasingly used to support clinicians in diagnosing multiple sclerosis (MS) and monitoring its progression. ...This review will summarize recent advances in brain neuroimaging in MS from the research setting to clinical applications....
Brain imaging is increasingly used to support clinicians in diagnosing multiple sclerosis (MS) and monitoring its progression. ...Thi …
Advances in imaging of brain abnormalities in neuromuscular disease.
Angelini C, Pinzan E. Angelini C, et al. Ther Adv Neurol Disord. 2019 May 6;12:1756286419845567. doi: 10.1177/1756286419845567. eCollection 2019. Ther Adv Neurol Disord. 2019. PMID: 31105770 Free PMC article. Review.
Brain atrophy, white matter abnormalities, and ventricular enlargement have been described in different neuromuscular diseases (NMDs). ...Correlations with clinical features have been observed with brain imaging characteristics and alterations were prominent in cong …
Brain atrophy, white matter abnormalities, and ventricular enlargement have been described in different neuromuscular diseases (NMDs) …
244 results